title: Single treatments that have lasting effects: some thoughts on the antidepressant effects of ketamine and botulinum toxin and the anxiolytic effect of psilocybin.
abstract: Recent clinical trials suggest that 3 single biological treatments have effects that persist. Based on research showing that the muscles involved in facial expressions can feed back to influence mood, a single trial diminishing glabella frown lines with botulinum toxin demonstrated a significant antidepressant effect for 16 weeks. Based primarily on research with animal models of depression suggesting that glutamate may be involved in depression, the N-methyl-D-aspartate antagonist ketamine has been tested in several trials. A single dose decreased depression for up to a week. The reported effects of the use of mushrooms containing psilocybin by a number of cultures around the world has stimulated several trials showing beneficial effects of a single dose of psilocybin for over a year in healthy people, and for up to 3 months in patients with anxiety disorders who have advanced cancer. This article discusses these studies, their rationale, their possible mechanisms of action, the future clinical research required to establish these therapies and the basic research required to optimize single treatments that have lasting effects.
authors.affiliation: Department of Psychiatry, McGill University, Montréal, Que. simon.young@mcgill.ca
authors.forename: Simon N
authors.initials: SN
authors.lastname: Young
mesh_terms: D000339:Affect / Q000187:drug effects; D000778:Anesthetics, Dissociative / Q000494:pharmacology; D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology; D018726:Anti-Dyskinesia Agents / Q000494:pharmacology; D001008:Anxiety Disorders / Q000188:drug therapy*; D001290:Attitude; D001519:Behavior / Q000187:drug effects; D001905:Botulinum Toxins / Q000494:pharmacology; D003866:Depressive Disorder / Q000188:drug therapy*; D005149:Facial Expression; D006213:Hallucinogens / Q000494:pharmacology; D006801:Humans; D007649:Ketamine / Q000494:pharmacology; D015990:Placebo Effect; D011562:Psilocybin / Q000494:pharmacology; D016896:Treatment Outcome
chemical_list: D000778:Anesthetics, Dissociative; D014151:Anti-Anxiety Agents; D018726:Anti-Dyskinesia Agents; D006213:Hallucinogens; D011562:Psilocybin; D007649:Ketamine; D001905:Botulinum Toxins